Published in Histopathology on April 01, 1996
The clinical course of bone metastases from breast cancer. Br J Cancer (1987) 4.93
Monoclonal antibody to cytokeratin for use in routine histopathology. J Clin Pathol (1984) 4.36
Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet (1991) 4.09
Assessment of response to therapy in advanced breast cancer. Br J Cancer (1977) 3.70
Stress and relapse of breast cancer. BMJ (1989) 3.07
The influence on survival of delay in the presentation and treatment of symptomatic breast cancer. Br J Cancer (1999) 2.89
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol (1998) 2.73
Reconstitution of interleukin 2 with albumin for infusion. Lancet (1990) 2.37
Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol (2000) 2.35
Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer (1996) 2.28
Who needs steroid receptor assays? Lancet (1989) 2.27
Comparison of intracavitary bleomycin and talc for control of pleural effusions secondary to carcinoma of the breast. Br J Surg (1989) 2.23
Nitric oxide synthase activity in human breast cancer. Br J Cancer (1995) 2.22
Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer (1998) 2.20
A monoclonal antibody that detects HLA-D region antigen in routinely fixed, wax embedded sections of normal and neoplastic lymphoid tissues. J Clin Pathol (1985) 2.00
Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry. J Clin Oncol (1990) 1.94
Oestrogen receptors and the response to endocrine therapy in advanced breast cancer. Br J Cancer (1978) 1.71
Inadequacy of iridium implant as sole radiation treatment for operable breast cancer. Eur J Cancer (1996) 1.70
Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer (1993) 1.68
Bone metastases and breast cancer. Cancer Treat Rev (1985) 1.67
Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet (1983) 1.61
Transcatheter embolisation to control severe bleeding in fungating breast cancer. Eur J Surg Oncol (1988) 1.53
Advanced breast cancer: use of resources and cost implications. Br J Cancer (1993) 1.48
Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme. Eur J Cancer (2003) 1.47
Chemotherapy of advanced breast cancer: outcome and prognostic factors. Br J Cancer (1993) 1.45
Bone scan flare predicts successful systemic therapy for bone metastases. J Nucl Med (1988) 1.44
Adjuvant chemotherapy for premenopausal breast cancer: a meta-analysis using quality-adjusted survival. Cancer J Sci Am (2006) 1.43
Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer. Eur J Cancer Clin Oncol (1983) 1.42
Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet (1992) 1.41
Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. Eur J Cancer (1981) 1.36
Expression of tumour necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue. Int J Cancer (1994) 1.35
"Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808). Eur J Cancer (1991) 1.35
Controlled trial of adjuvant chemotherapy with melphalan for breast cancer. Lancet (1983) 1.35
Expression of low molecular weight cytokeratin proteins in cervical neoplasia. J Pathol (1986) 1.31
A new combined approach to the conservative treatment of early breast cancer. Surgery (1984) 1.30
Sclerosing lymphocytic lobulitis of the breast--evidence for an autoimmune pathogenesis. Histopathology (1991) 1.30
Mechanism of action of adjuvant chemotherapy in early breast cancer. Lancet (1986) 1.30
Liver metastases from breast cancer: the relationship between clinical, biochemical and pathological features and survival. Eur J Cancer (1990) 1.29
Risk of complications from bone metastases in breast cancer. implications for management. Eur J Cancer (2000) 1.26
Angiogenesis and inflammation in invasive carcinoma of the breast. J Clin Pathol (1997) 1.26
Primary hypothyroidism associated with interferon therapy of breast cancer. Lancet (1985) 1.26
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: an update of the Guy's/Manchester trial. J Clin Oncol (1990) 1.25
Mastectomy or conservation for early breast cancer: psychological morbidity. Eur J Cancer (1992) 1.22
Prognosis in inoperable stage III carcinoma of the breast. Eur J Cancer (1977) 1.22
DNA index, S-phase fraction, histological grade and prognosis in breast cancer. Br J Cancer (1990) 1.21
Psychiatric disorder in patients with advanced breast cancer: prevalence and associated factors. Eur J Cancer (1993) 1.21
Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry. Br J Cancer (1989) 1.21
Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil for breast cancer. Lancet (1984) 1.18
Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Br J Cancer (1988) 1.18
Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy? Br J Cancer (2004) 1.18
The classification of ductal carcinoma in situ and its association with biological markers. Semin Diagn Pathol (1994) 1.18
Histochemical studies with an estrogen receptor-related protein in human breast tumors. Cancer Res (1986) 1.15
Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer (1999) 1.14
Antigens of small-cell lung cancer. First International Workshop. Lancet (1987) 1.13
Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland. Eur J Cancer (1978) 1.13
Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother Emphasis Tumor Immunol (1996) 1.13
Management of locally advanced and disseminated breast cancer. Lancet (1981) 1.13
Metastatic eccrine porocarcinoma: response to docetaxel (Taxotere) chemotherapy. Ann Oncol (2001) 1.12
A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma. Br J Cancer (1987) 1.11
Expression of epithelial and neural antigens in small cell and non small cell lung carcinoma. J Pathol (1986) 1.11
Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol (1995) 1.10
Antigens of lung cancer: results of the second international workshop on lung cancer antigens. J Natl Cancer Inst (1991) 1.07
Safety of tamoxifen. Lancet (1978) 1.07
Reappraisal of the baseline bone scan in breast cancer. J Nucl Med (1988) 1.07
Biochemical prediction of response of bone metastases to treatment. Br J Cancer (1988) 1.07
Expression of sialyl-Tn predicts the effect of adjuvant chemotherapy in node-positive breast cancer. Br J Cancer (1994) 1.07
Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours. Genes Chromosomes Cancer (1999) 1.07
3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer. Br J Cancer (1987) 1.06
Augmentation of cytotoxic drug action by antibodies directed at cell surface. Nature (1974) 1.06
Human parvovirus B19 and hydrops fetalis. Lancet (1988) 1.05
Iridium implant treatment without external radiotherapy for operable breast cancer: a pilot study. Eur J Cancer (1991) 1.04
Invasive lobular and invasive ductal carcinoma of the breast show distinct patterns of vascular endothelial growth factor expression and angiogenesis. J Pathol (1998) 1.04
Estrogen receptors and response to endocrine therapy and cytotoxic chemotherapy in advanced breast cancer. Cancer (1980) 1.04
A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br J Cancer (1996) 1.03
Sequential bone scans and chest radiographs in the postoperative management of early breast cancer. Br J Surg (1983) 1.03
Serum progesterone at the time of surgery and survival in women with premenopausal operable breast cancer. Eur J Cancer (1994) 1.03
The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer (1994) 1.03
Mitoxantrone for the treatment of advanced breast cancer: single-agent therapy in previously untreated patients. Eur J Cancer Clin Oncol (1984) 1.03
Results of the central data analysis. Br J Cancer Suppl (1991) 1.02
Osteocalcin: a potential marker of metastatic bone disease and response to treatment. Eur J Cancer Clin Oncol (1988) 1.02
DNA flow cytometry and response to preoperative chemotherapy for primary breast cancer. Eur J Cancer (1992) 1.02
Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests. Br J Cancer (1992) 1.01
Do patients with advanced breast cancer benefit from chemotherapy? Br J Cancer (1998) 1.01
Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients. Br J Cancer (1999) 1.00
Corticosteroids for elderly patients with breast cancer. Cancer (1981) 1.00
A comparison of intracavitary talc and tetracycline for the control of pleural effusions secondary to breast cancer. Eur J Cancer Clin Oncol (1986) 1.00
Classification of testicular cancer in incidence and mortality statistics. Br J Cancer (1987) 0.99
Family history and survival in premenopausal breast cancer. Br J Cancer (1998) 0.99
Iododoxorubicin in advanced breast cancer: a phase II evaluation of clinical activity, pharmacology and quality of life. Br J Cancer (1994) 0.98